James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. According to the complaint, on June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MAS ...

BREAKING: Futures Edge Up, Alibaba Leads China Stocks Higher Shares of Acadia Pharmaceuticals (ACAD) toppled Wednesday after the biotech company's experimental treatment for a rare, genetic disorder failed in Phase 3 testing. Analysts largely expected the drug, dubbed carbetocin, to miss its mark in patients with Prader-Willi syndrome. In this condition, a deletion or mutation of a specific gene causes physical, intellectual, developmental and behavioral symptoms. Acadia intended for its drug to treat exces ...

uniQure (NasdaqGS:QURE) Update / Briefing September 24, 2025 08:30 AM ET Company ParticipantsChiara Russo - Senior Director - IRMatt Kapusta - CEO & Executive DirectorWalid Abi-Saab - Chief Medical OfficerSarah Tabrizi - ProfessorKylie O’Keefe - Chief Customer & Strategy OfficerPaul Matteis - MD & Head - Therapeutics ResearchJoseph Schwartz - Senior MD - Rare DiseasesDebjit Chattopadhyay - Senior Managing DirectorUy Ear - VP of US Healthcare - BiotechnologySalveen Richter - Biotechnology Equity ResearchElli ...

Investor Day This presentation includes references to certain financial measures that are not calculated in accordance with GAAP. Reconciliation to the most directly comparable GAAP financial measure may be found in the earnings release furnished to the SEC. We define our non-GAAP measures as the applicable GAAP measure adjusted for the impacts of stock-based compensation and related employer payroll tax payments, contingent consideration, amortization of intangible assets, unrealized gains and losses on ma ...

GRAIL (NasdaqGS:GRAL) FY Conference September 24, 2025 08:00 AM ET Company ParticipantsJoshua Ofman - PresidentConference Call ParticipantsEve Burstein - US Life Science Tools & Diagnostics AnalystEve BursteinIt's a hardy group that's here at 8:01 A.M. I think there'll be a bigger group at about 8:05 A.M., but we'll go ahead and get started because I have a lot to ask. Excited to be here. Thank you guys all for being here. For anyone that doesn't know me, my name is Eve Bernstein. I cover U.S. life science ...

VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the "Offering") of 14,636,363 common shares of the Company (the “Common Shares"), w ...

Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies have proven to be effective in AR-V7 driven tumors BOSTON and LONDON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced key preclinical data demonstrating the potential of its novel ...

LAS VEGAS, Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB:Â AVAI)Â ("Avant" or the "Company"), a Nevada-based corporation, Art-Islets Pte. Ltd. ("Art-Islets") and Austrianova (SGAustria Pte. Ltd.), both Singapore-based biotechnology companies, today announced the formation of a groundbreaking Joint Venture and License Agreement aimed at revolutionizing a diabetes treatment through innovative stem cell and encapsulation technologies. Continue Reading Avant Technologies This strategic collabor ...

Pivotal Phase I/II AMT-130 Huntington's Disease Update September 24, 2025 Disclaimer This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may ...

Commercial Readiness for Acquired Hypothalamic Obesity September 24, 2025 ® © Rhythm® Pharmaceuticals, Inc. All rights reserved. Forward-looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and that involve risks and uncertainties, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical progress of our products and product candidates, including setmel ...